RADIOLOGY HELP DOCUMENTS Procedures and Preps
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Master Agreement
MASTER AGREEMENT Between The Medical Society of Prince Edward Island And The Government of Prince Edward Island And Health PEI April 1, 2015 - March 31, 2019 MASTER AGREEMENT TABLE OF CONTENTS SECTION A - GENERAL Article A1. Purpose of Agreement .......................................................................................1 Article A2. Application, Duration and Amendments ..........................................................1 Article A3. Interpretation and Definitions ...........................................................................1 Article A4. Recognition .......................................................................................................3 Article A5. Administrative Authority ..................................................................................4 Article A6. Information .......................................................................................................4 Article A7. Correspondence.................................................................................................5 Article A8. Negotiations ......................................................................................................5 Article A9. General Grievance Procedure ...........................................................................6 Article A10. Mediation ..........................................................................................................7 Article A11. Interest Arbitration ............................................................................................8 -
A Comparison of Imaging Modalities for the Diagnosis of Osteomyelitis
A comparison of imaging modalities for the diagnosis of osteomyelitis Brandon J. Smith1, Grant S. Buchanan2, Franklin D. Shuler2 Author Affiliations: 1. Joan C Edwards School of Medicine, Marshall University, Huntington, West Virginia 2. Marshall University The authors have no financial disclosures to declare and no conflicts of interest to report. Corresponding Author: Brandon J. Smith Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia Email: [email protected] Abstract Osteomyelitis is an increasingly common pathology that often poses a diagnostic challenge to clinicians. Accurate and timely diagnosis is critical to preventing complications that can result in the loss of life or limb. In addition to history, physical exam, and laboratory studies, diagnostic imaging plays an essential role in the diagnostic process. This narrative review article discusses various imaging modalities employed to diagnose osteomyelitis: plain films, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, bone scintigraphy, and positron emission tomography (PET). Articles were obtained from PubMed and screened for relevance to the topic of diagnostic imaging for osteomyelitis. The authors conclude that plain films are an appropriate first step, as they may reveal osteolytic changes and can help rule out alternative pathology. MRI is often the most appropriate second study, as it is highly sensitive and can detect bone marrow changes within days of an infection. Other studies such as CT, ultrasound, and bone scintigraphy may be useful in patients who cannot undergo MRI. CT is useful for identifying necrotic bone in chronic infections. Ultrasound may be useful in children or those with sickle-cell disease. Bone scintigraphy is particularly useful for vertebral osteomyelitis. -
Members | Diagnostic Imaging Tests
Types of Diagnostic Imaging Tests There are several types of diagnostic imaging tests. Each type is used based on what the provider is looking for. Radiography: A quick, painless test that takes a picture of the inside of your body. These tests are also known as X-rays and mammograms. This test uses low doses of radiation. Fluoroscopy: Uses many X-ray images that are shown on a screen. It is like an X-ray “movie.” To make images clear, providers use a contrast agent (dye) that is put into your body. These tests can result in high doses of radiation. This often happens during procedures that take a long time (such as placing stents or other devices inside your body). Tests include: Barium X-rays and enemas Cardiac catheterization Upper GI endoscopy Angiogram Magnetic Resonance Imaging (MRI) and Magnetic Resonance Angiography (MRA): Use magnets and radio waves to create pictures of your body. An MRA is a type of MRI that looks at blood vessels. Neither an MRI nor an MRA uses radiation, so there is no exposure. Ultrasound: Uses sound waves to make pictures of the inside of your body. This test does not use radiation, so there is no exposure. Computed Tomography (CT) Scan: Uses a detector that moves around your body and records many X- ray images. A computer then builds pictures or “slices” of organs and tissues. A CT scan uses more radiation than other imaging tests. A CT scan is often used to answer, “What does it look like?” Nuclear Medicine Imaging: Uses a radioactive tracer to produce pictures of your body. -
INTERPRETATION of the 67Gd PHOTOSCAN
INTERPRETATION OF THE 67Gd PHOTOSCAN Steven M. Larson, Michael S. Milder, and Gerald S. Johnston National Institutes of Health, Bethesda, Maryland Gallium-67 citrate is used to locate sites of of these investigators was not achieved, several im tumor involvement throughout the body. In or portant observations were made. The distribution of der to make proper use of this new agent, a carrier-free "7Ga was predominantly found within knowledge of the normal ' t.u distribution and the liver, spleen, kidney, and bone in rats. The addi physiological variations is necessary. For this tion of stable gallium caused a progressive increase report, over 400 whole-body rectilinear scans in relative concentration within the skeleton and a using 35 fid/kg "~Ga citrate were reviewed. At relative decrease in soft tissue concentration. As a 48 hr, normal 6~Ga activity is concentrated in result of this early work, ^Ga with a carrier was the axial skeleton, liver, spleen, and around the later evaluated as a bone scanning agent, and it was large joints. Foci of uptake are often seen in while scanning the bones of a patient with Hodgkin's the salivary, lacrimal, and mammary glands. disease that the tumor-specific properties of 67Ga- Activity is also found in the region of the naso citrate were discovered (2). pharynx. Under certain physiological condi The distribution of 07Ga in humans has subse tions, intense localisation may occur within the quently been studied (77-73). When carrier-free breast, bowel, and long bones. These variations 07Ga-citrate is injected intravenously, the majority may mimic malignant tumors. -
GALLIUM SCAN Information Brochure
GALLIUM SCAN Information Brochure North Shore Radiology & Nuclear Medicine North Shore Private Hospital Westbourne Street, St Leonards 2065 Tel: (02) 8425 3684, Fax: (02) 8425 3688 Nuclear Medicine Physicians Dr Elizabeth Bernard FRACP Dr Paul Roach FRACP INSTRUCTIONS FOR PATIENTS HAVING A GALLIUM SCAN What is it? This is a test which is used to detect a variety of conditions, including infections, abscesses and certain tumours such as lymphoma. How is the test done and how long does it take? The test involves an injection into a vein of a small amount of a radioactive compound called Gallium. A specialised camera is then used to take pictures of your body. On the first day, the test will be explained to you and a technologist will give you the injection gallium (this only takes no more than 15 minutes). You will return two days later for the scan which may take 30-90 minutes depending on what your doctor is looking for. (You are not scanned earlier because it takes several days for any abnormality to appear on the scan.) You may need to return for further scans over the next few days as gallium is normally excreted into the bowel and it may take up to 1 week for the bowel to clear. Is it painful and are there any side effects? No. There are no side effects or reactions from the injection. The injection does NOT contain iodine and is therefore safe to give even if you have had a previous allergic reaction to contrast injections. Although you will be required to keep still during the scan, the procedure itself is completely painless. -
Gallium Study: Performed to Detect Or Localize Areas of Chronic Infection Or Tumors • There Are No Preparations Needed For
Gallium Study: performed to detect or localize areas of chronic infection or tumors There are no preparations needed for this exam; although it would be beneficial if the patient is well-hydrated and only if it does not interfere with other testing or procedures. If a gallium scan is needed, it should be done before any tests that use barium (such as a barium enema). Taking a medicine (such as Pepto-Bismol) that contains bismuth can also interfere with a gallium scan. In some cases, patients may be required to do a mild bowel prep prior to or upon completion of this study. If the patient is under the age of 50 and has NOT had a hysterectomy, a urine pregnancy test will be required at no charge to the patient. The patient needs to arrive 30 minute prior to the appointment time for the pregnancy test to be administered. If the patient is breast feeding, please consult the department for further instruction. The duration of this exam can range from six to 72 hours. The patient is injected with a radioactive tracer in the vein. The patient returns to the Radiology department six hours after the time of the injection. The patient lies on the imaging table and is scanned from the head to mid-thigh or over a particular area of interest. Imaging takes about 1 hour. The patient returns at 24 hours and again at 48 hours to repeat the scan. The patient may also need to return after 72 hours for another scan. The patient is asked to bring any prior films or reports of x-rays, ultrasound, MRI or CT scans ONLY if the studies were NOT performed at United Regional. -
PET/CT & Nuclear Medicine in Clinical Practice
The 8 th | Snowmass 2017: PET/CT & Nuclear Medicine in Clinical Practice Friday, February 24, 2017 Westin Snowmass Resort • Snowmass Village, Colorado Educational Symposia TABLE OF CONTENTS FRIDAY, FEBRUARY 24, 2017 Fluoride PET/CT Bone Imaging (Kevin L. Berger, M.D.) ................................................................................................. 221 Bone Scintigraphy (Andrew T. Trout, M.D.) .................................................................................................................. 235 Improving Efficiency in PET/CT Practice (Paul Shreve, M.D.) ......................................................................................... 249 Infection and Inflammation Imaging (Don C. Yoo, M.D.) ................................................................................................ 263 Clinical Molecular Imaging: Beyond FDG and PET/CT (Arif Sheikh, M.D.) ..................................................................... 275 SAVE THE DATES - 2018 Winter Symposia 221 222 INTRODUCTION DIAGNOSTIC METHODS Modalities 18F NaF was one of the original • Planar bone scan agents. In fact, FDA • X-Ray • CT approved 18F NaF for clinical use in • MRI 1972. • SPECT/CT • PET • PET/CT Now, there are many choices to Bone Imaging Agents diagnose a bone metastasis. • 99mTc medronate (MDP) • 99mTc oxidronate (HDP) • 18F FDG • 18F NaF INTRODUCTION 18 INTRODUCTION HOW DOES F NaF WORK? ADVANTAGES OF 18F NaF PET/CT BONE SCANS • 18F produced by proton bombardment of 180, represents a precursor in pathway of 18F for -
Application of Fluorine-18-Deoxyglucose Positron Emission Tomography and Gallium Scan for Assessment in a Patient with Adult-Onset Still’S Disease
Arch Rheumatol 2016;31(2):180-183 doi: 10.5606/ArchRheumatol.2016.5754 CASE REPORT Application of Fluorine-18-Deoxyglucose Positron Emission Tomography and Gallium Scan for Assessment in a Patient With Adult-Onset Still’s Disease Jing-Uei HOU, Shih-Chuan TSAI, Wan-Yu LIN Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan ABSTRACT A 53-year-old female patient suffered from pain in almost her entire body, particularly the joints. Chest computed tomography revealed multiple lymphadenopathies over cervical, mediastinal, and axillary areas. A fluorine-18-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) revealed increased FDG uptake in many lymph nodes and the spleen. Lymphoma was suspected. However, the result of a biopsy showed no malignancy, and the gallium-67 citrate scan showed no gallium-avid tumor throughout the whole body. Adult-onset Still's disease was diagnosed and the patient responded well to steroid therapy. The follow-up PET/CT six months later showed complete remission of the FDG-avid lesions seen in the previous PET/CT. Our study suggests that FDG PET/CT combined with gallium-67 scan may be helpful in diagnosing patients with adult-onset Still’s disease. In addition, the use of FDG PET/CT alone may be useful for the evaluation of disease distribution, disease activity, and therapeutic response. Keywords: Adult-onset Still’s disease; fluorine-18-deoxyglucose; gallium-67; positron emission tomography/computed tomography. Adult-onset Still’s disease (AOSD) is an CASE REPORT inflammatory disorder of unknown cause. “Still’s disease” was first described in children by George A 53-year-old female patient suffered from pain Still in 1896.1 In 1971, the term “Adult-onset over most of her body, particularly the joints and Still’s disease” was used to describe patients the throat. -
Gallium Imaging What to Expect During the Test • the Test Will Take 2 - 3 Days
Nuclear Medicine Patient Information Gallium Imaging What to expect during the test • The test will take 2 - 3 days. Welcome to VCU Health Nuclear Medicine. We are Day 1 located in the Gateway Building, 2nd floor, 1200 East . A needle (IV) will be placed in a vein (intravenous Marshall Street. Our hours of operation are Monday catheter). through Friday, 7 am to 5 pm. Advanced scheduling is . A radioactive tracer will be administered through required for all nuclear medicine exams. Please review the IV. the following information about your test. Please call . You may go on with normal activities in between (804) 828-6828 to schedule your test or if you have any the injection and scan (eat and drink as normal). questions about your nuclear medicine exam. Day 2 (48 hours after injection) . You will lie down while the camera takes pictures What is it? of your whole body and possibly a SPECT (360 Imaging to detect certain types of infection, certain degree picture of your body) for 1 – 2 hours. inflammatory diseases or tumors. The images will be checked for quality by our Physician and more pictures may be needed. Why are you having this test? Day 3 (72 hours after injection) A gallium scan is done to: . You will lie down while the camera takes pictures • Detect the source of an infection that is causing a of your whole body and possibly a SPECT (360 fever (called a fever of unknown origin). degree picture of your body) for 1 – 2 hours. • Detect an abscess or certain infections, . -
S.P. Strijk Stellingen
INIS-mf —11067 y i; ••Ht g S.P. STRIJK STELLINGEN 1. Het verschil in diagnostische nauwkeurigheid tussen CT en lymfografie bij patiënten met maligne lymfoom berust voornamelijk op een verschil in sensitiviteit ten nadele van CT. 2. CT is geen alternatief voor stadiëringslaparotomie. 3. De informatie verkregen met behulp van CT en lymfo- grafie is voor 85% overlappend en voor 15% aanvullend. Tegenstrijdige informatie kan meestal afdoende ver- klaard worden. 4. Het routinematig verrichten van een CT van de thorax als onderdeel van het stadiëringsonderzoek bij patiën- ten met de ziekte van Hodgkin of non-Hodgkin lymfoom is niet zinvol. 5. De in-vivo bepaling van de miltgrootte met behulp van de CT-miltindexberekening kan aanwijzingen geven over eventuele lymfoomlocalisatie in de milt bij .patiënten met de ziekte van Hodgkin of non-Hodgkin lymfoom. 6. Het optreden van lymfklierverkalkingen bij de ziekte van Hodgkin is een prognostisch gunstig teken. 7. Het verrichten van een lymfografie na een abdominale CT-scan levert alleen additionele informatie op wanneer de CT géén of twijfelachtige afwijkingen laat zien. 8. Magnetic Resonance Imaging (MRI) is een gevoelige methode voor het opsporen van afwijkingen in het been- merg bij patienter, met leukemie, maligne lymfoom of metastasen. (DO Oison et al., Invest. Radiol. 1986; 21: 540-546). 9. Wanneer bij patiënten met een niet-seminomateuza testistumor wordt gekozen voor een zogenaamd "wait and see" beleid, dan dient bij screening op retroperitone- ale lymfkliermetastasen zowel een abdominale CT-scan als een lymfografie te worden verricht. 10. Bij de bepaling van de resectabiliteit van een pancreastumor kan een percutané transhepatische porto- grafie (PTP) bij een groot deel van de patiënten worden vermeden door het uitvoeren van een intra-arteriële digitale subtractie angiografie (i.a. -
Iranian Journal of Nuclear Medicine
IRANIAN JOURNAL OF NUCLEAR MEDICINE Iranian Journal of Nuclear Medicine is a peer-reviewed biannually journal of the Research Institute for Nuclear Medicine, Tehran University of Medical Sciences, covering basic and clinical nuclear medicine sciences and relevant application. The journal has been published in Persian (Farsi) from 1993 to 1994, in English and Persian with English abstract from 1994 to 2008 and only in English language form the early of 2008 two times a year. The journal has an international editorial board and accepts manuscripts from scholars working in different countries. Chairman & Chief Editor: Saghari, Mohsen; MD Associate Editor and Executive Manager: Beiki, Davood; PhD Scientific Affairs: Eftekhari, Mohammad; MD and Fard-Esfahani, Armaghan; MD Editorial Board Alavi, Abbas; MD (USA) Grammaticos, Philip C.; MD (Greece) Ay, Mohammad Reza; PhD (Iran) Mirzaei, Siroos; MD (Austria) Beheshti, Mohsen; MD (Austria) Najafi, Reza; PhD (Iran) Beiki, Davood; PhD (Iran) Rahmim, Arman; PhD (USA) Cohen, Philip; MD (Canada) Rajabi, Hossein; PhD (Iran) Dabiri-Oskooei, Shahram; MD (Iran) Saghari, Mohsen; MD (Iran) Eftekhari, Mohammad; MD (Iran) Sarkar, Saeed; PhD (Iran) Fard-Esfahani, Armaghan; MD (Iran) Zakavi, Seyed Rasoul; MD (Iran) ------------------------------------------------------------------------------------------------------- Editorial Office Iranian Journal of Nuclear Medicine, Research Institute for Nuclear Medicine, Shariati Hospital, North Kargar Ave. 1411713135, Tehran, Iran Tel: ++98 21 88633333, 4 Fax: ++98 21 88026905 E-mail: [email protected] Website: http://irjnm.tums.ac.ir Indexed in/Abstracted by EMBASE, Scopus, ISC, DOAJ, Index Copernicus, EBSCO, IMEMR, SID, IranMedex, Magiran Vol 20 , Supplement 1 2012 INSTRUCTION TO AUTHORS Aims and Scope Review articles Iranian Journal of Nuclear Medicine is a peer-reviewed biannually These are, in general, invited papers, but unsolicited reviews, if of journal of the Research Institute for Nuclear Medicine, Tehran good quality, may be considered. -
4Th Quarter 2001 Medicare a Bulletin
In This Issue... Medicare Guidelines on Telehealth Services Benefit Expansion, Coverage and Conditions for Reimbursement of These Services ............... 5 Medicare eNews Now Available Join Florida Medicare eNews Mailing List to Receive Important News and Information ........ 9 Expansion of Coverage on Percutaneous Transluminal Angioplasty Coverage Expansion and Claim Processing Instructions for Hospital Inpatient Services ..... 12 Skilled Nursing Facility Consolidated Billing Clarification to Health Insurance Prospective Payment System Coding and Billing Guidelines .............................................................................................................................. 15 Final Medical Review Policies 10060, 55873, 67221, 71250, 74150, 84155, 85007, 88141, 92225, 93303, A0430, G0030,G0104, G0108, J1561, J1745, J9212, and M0302 ...................................... 22 Outpatient Prospective Payment System Update and Changes to the Hospital Outpatient Prospective Payment System ...................... 87 Bulletin Reader Survey Provide your Comments and Feedback on the Medicare Part A Publication and/or our Provider Web Site ................................................................................................................ 103 Features From the Medical Director 3 he Medicare A Bulletin should be shared with all Administrative 4 T health care practitioners and General Information 5 managerial members of the General Coverage 11 provider/supplier staff. Publications issued after End Stage Renal Disease 13